PRIOR AUTHORIZATION POLICY

POLICY: Phenylketonuria – Kuvan® (sapropterin dihydrochloride tablets and powder for oral solution – BioMarin Pharmaceuticals)

TAC APPROVAL DATE: 05/15/2019

OVERVIEW
Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4) responsive phenylketonuria (PKU).1 The medication should be used with a Phe-restricted diet. Kuvan works by increasing phenylalanine hydroxylase (PAH). It is a synthetic preparation of naturally occurring BH4, which is a cofactor for the enzyme PAH. PAH hydroxylates Phe in an oxidative reaction to form tyrosine. In patients with PKU, PAH activity is deficient or absent. Treatment with BH4 can activate residual PAH enzyme, improve the normal oxidative metabolism of Phe, and decrease Phe levels in some patients. In patients with PKU who are responsive to treatment, blood Phe levels decrease within 24 hours after administration, although maximal effect on Phe levels may take up to 1 month. Blood Phe levels should be checked after 1 week of treatment and periodically for 1 month. If blood Phe does not decrease from baseline at the 10 mg/kg/day dose, the dose may be increased to 20 mg/kg/day. Patients whose blood Phe does not decrease after 1 month of treatment at 20 mg/kg/day are non-responders and treatment with Kuvan should be discontinued. Once responsiveness has been determined, the dose may be adjusted within the range of 5 to 20 mg/kg/day.

PKU is the most prevalent disorder due to an inborn error in amino acid metabolism.3 It is caused by mutations in the PAH gene.3 The annual incidence is about 1:15,000 births in the US. Genotypes of the disease range from a mild increase in blood Phe concentrations to a severe classic phenotype with very pronounced increases in HPA, which if not treated, can result in profound and irreversible mental disability.3 Other manifestations of PKU, if untreated, can include eczematous rash, autism, seizures, motor defects, developmental problems, impaired memory, behavioral issues (e.g., attention deficit hyperactivity disorder [ADHD]) and psychiatric behavior. Early diagnosis and prompt intervention is important and routine screening programs are in place for newborns. Women with untreated or poorly treated PKU who are pregnant pose a particular health concern due to fetal exposure to teratogenic concentrations of Phe. Dietary restrictions in Phe are a mainstay in PKU management. Patients with PKU have to intake PHE-free formula and avoid foods that are protein-rich (e.g., meats, fish, eggs, standard bread, most cheeses, nuts and seeds). Other foods and beverages that contain aspartame, flour, soy, beer, or cream should be avoided. Low-protein foods that are natural may be consumed in restricted amounts, such as potatoes, some vegetables, and most cereals. During infancy, adherence to dietary restrictions is more manageable but as children grow older and become adults the dietary limitations can become burdensome.

Guidelines/Recommendations
According to the European guidelines for phenylketonuria (2017), there is consensus in the literature that patients with blood phenylalanine concentration > 600 µmol/L should be treated.8 There is also consensus that patients with blood Phe concentration < 360 µmol/L can remain untreated, but should be monitored. Patients with blood Phe concentration between 360 to 600 µmol/L should be treated until 12 years of age. Treatment for life is recommended for any patient with PKU; however, it is also noted that patients ≥ 12 years of age with blood Phe concentration < 600 µmol/L do not require treatment. All adults with PKU should have lifelong systematic follow-ups in specialized metabolic centers, due to specific risks which may occur during adulthood. With regards to target Phe levels, in treated PKU patients up to 12 years of age,
age, the target Phe levels should be 120 to 360 µmol/L; in treated PKU patients ≥ 12 years of age, the target Phe levels should be 120 to 600 µmol/L.

The American College of Medical Genetics and Genomics (ACMG) published practice guidelines (2014) for the diagnosis and management of PAH deficiency.\(^9\) The guidelines recommend initiating treatment as early as possible, preferably within the first week of life with a goal of having blood PHE levels in the treatment range within the first 2 weeks. Dietary restriction of PHE intake is the mainstay of therapy for PKU. Blood PHE levels in all patients should be maintained in the range of 120 to 360 µmol/L. Newly diagnosed infants should be monitored at least weekly for their levels at least until 1 year of age. For children 1 through 12 years of age, biweekly to monthly monitoring of levels is adequate and for adolescents and adults who are stable and well-controlled, monthly testing is usually adequate. The guidelines state that approximately 25% to 50% of patients with PAH deficiency are responsive to Kuvan. A significant decline in blood PHE level is expected in responders once treatment is initiated (with PHE-restricted diet); however, patients in the lower end of the treatment range (≤ 180 µmol/L) rarely show a decrease in blood PHE level even if they are responsive to Kuvan. In these patients, responsiveness is determined by adding PHE to the diet in a stepwise method. An improvement in neuropsychiatric symptoms or increase in PHE tolerance without a decrease in blood PHE levels is sufficient reasoning to continue therapy. According to the guidelines, there is strong evidence to support life-long treatment and maintenance of metabolic control in patients with PAH deficiency.

**POLICY STATEMENT**

Prior authorization is recommended for prescription benefit coverage of Kuvan tablets and powder for oral solution. Because of the specialized skills required for evaluation and diagnosis of patients treated with Kuvan as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Kuvan to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for 1 year in duration unless otherwise noted below.

**Automation:** None.

**RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Kuvan tablets or Kuvan powder for oral solution is recommended in those who meet the following criteria:

**FDA-Approved Indications**

1. **Hyperphenylalaninemia (HPA) due to Phenylketonuria (PKU) – Initial Therapy.** Approve for 12 weeks if the patient meets the following criteria (A and B):
   - A) Kuvan is prescribed in conjunction with a phenylalanine (Phe)-restricted diet; AND
   - B) The medication is prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases).

   Kuvan is indicated to reduce blood Phe levels in patients with HPA due to BH4-responsive PKU in conjunction with a Phe-restricted diet.\(^1\)

2. **Hyperphenylalaninemia (HPA) due to Phenylketonuria (PKU) – Patients Continuing Therapy [Maintenance Therapy].** Approve for 1 year if the patient meets the following criteria (A or B):
   - A) The patient has had a clinical response (e.g., cognitive and/or behavioral improvements) as determined by the prescribing physician; OR
B) The patient has achieved a ≥ 20% reduction in blood phenylalanine concentration from pre-treatment baseline (i.e., blood phenylalanine concentration before starting Kuvan therapy).

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Kuvan has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

1. Concomitant Therapy with Kuvan and Palynziq® (pegvaliase-pqpz for injection). There are no data available to support the concomitant use of Palynziq and Kuvan. In the Palynziq pivotal studies patients were required to discontinue use of Kuvan at least 14 days prior to the first dose of Palynziq.

2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

# HISTORY

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes*</th>
<th>TAC Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual revision</td>
<td>No criteria changes</td>
<td>03/18/2015</td>
</tr>
<tr>
<td>Annual revision</td>
<td>No criteria changes</td>
<td>03/30/2016</td>
</tr>
<tr>
<td>Annual revision</td>
<td>No criteria changes</td>
<td>04/05/2017</td>
</tr>
<tr>
<td>Annual revision</td>
<td>No criteria changes</td>
<td>04/25/2018</td>
</tr>
<tr>
<td>Selected revision</td>
<td>Added &quot;[Maintenance Therapy]&quot; qualifier to patients continuing Kuvan indication. Added &quot;pre-treatment&quot; before baseline in patients continuing therapy criteria. Also defined pre-treatment baseline as prior to starting Kuvan therapy. Under Conditions Not Recommended for Approval, added concomitant therapy with Palynziq and Kuvan.</td>
<td>05/30/2018</td>
</tr>
<tr>
<td>Annual revision</td>
<td>No criteria changes</td>
<td>05/15/2019</td>
</tr>
</tbody>
</table>

TAC – Therapeutic Assessment Committee; * For further summary of criteria changes, refer to respective TAC minutes available at: [http://esidepartments/sites/Dep043/Committees/TAC/Forms/AllItems.aspx](http://esidepartments/sites/Dep043/Committees/TAC/Forms/AllItems.aspx)